Sitagliptin Added-on to Insulin Study (0431-051)

NCT00395343 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

641

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: sitagliptin phosphate
DRUG: Comparator : placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC